Clinical research
Selecta Biosciences, Inc. (NASDAQ: SELB), today announced top-line results from a joint Selecta and AskBio Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTORTM platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies.
Regeneron Pharmaceuticals announced more positive findings from its ongoing Phase III trial on the use of REGEN-COV to prevent COVID-19 in uninfected persons who have been exposed to the virus.
Bristol Myers Squibb’s Phase III CheckMate -816 trial hit the primary endpoint in an interim analysis.
GlaxoSmithKline is lining up a potential new treatment for patients with anemia due to chronic kidney disease following positive results in a Phase III study.
Autolus is currently working on advancing obecabtagene autoleucel, its CD19 CAR T cell investigational therapy product candidate, in addition to other applications of obe-cel in B-cell malignancies.
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
Kindness. Respect. Innovation. Only one of those words typically features in biotech mission statements, but at Ikena Oncology, all three are important – and have been from day one.
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
Pfizer plans to seek Emergency Use Authorization for an antiviral COVID-19 treatment following an interim analysis of Phase II/III data that show statistically and clinically meaningful results.
Sangamo Therapeutics announced positive preliminary findings from its ongoing Phase I/II STAAR clinical trial in Fabry disease.
PRESS RELEASES